Archives: Speakers

Lori Kahler is the Founder and Managing Director of The RC Insight Group.  Ms. Kahler has over 25 years’ experience in the medical device industry that spans across operations, quality, compliance, regulatory and clinical affairs.  Positions previously held include Global Vice President of Operations and QARA for INVO Bioscience, where Ms. Kahler was instrumental in achieving FDA De Novo clearance for INVO Bioscience’s innovative INVOcell® System; Director of Regulatory and Compliance for Samsung Electronics America (Health and Medical Equipment); Vice President of Regulatory and Clinical Operations for Ximedica; and Global Director of Quality Operations and Regulatory Affairs/ Managing Director Asia Pacific Region for Agfa Healthcare.

Dan DeBonis is one of the pioneers and leaders at the forefront of innovation for eCOA, outcome analytics and the integration of digital technologies in clinical research.   He is an entrepreneur, a co-founder of several companies, including Concordant Rater Systems, which  became part of what is now Signant Health in 2010.   Throughout his career, he has integrated key stakeholders, including clinicians, developers, KOLs, patients and regulators, into technology driven solutions to improve the quality and integrity of clinical trial data.   More recently, Dan has been a leader on COVID-19 response and mitigation strategies for Signant Health and our clients.   He has served as an advisor to a range of companies from start-ups to large pharmaceutical companies.   Dan is the author of a patent and publications on technologies in clinical research.  He is a graduate of Yale University, and resides with his young family in Boston.

Angela Luttick is a virologist with more than 20 years’ experience in the discovery, development and commercialisation of novel drugs. Well accustomed to leading multidisciplinary teams and experienced in the generation and integrity of key discovery-stage biological data required for the preparation of IND packages used in filing numerous FDA submissions. Angela is a co-founder and executive director at 360biolabs and leads business development and strategy for company growth.

Cameron Johnson is considered one of the most experienced Phase I Clinical Trial professionals in Australia, having held senior management roles within three of the four established Phase I Australian Clinical Trial companies.

Cameron’s Phase I experience extends into Europe and the Clinical Research Organization (CRO) industry, where he managed Clinical Trial facilities across Australia and New Zealand. He joined Nucleus Network in September 2013 as Chief Operating Officer before moving into the position of Chief Executive Officer (CEO) in May 2016.

Dr. Sara De Pelsmaeker graduated as a Bio-Engineer in Food Technology and Nutrition in 2009 at Ghent University. She obtained her Doctoral Degree in Applied Biological Sciences in 2016 at Ghent University with an expertise in sensory analysis. During her PhD at the department Agricultural Economics she gained extensive knowledge on business development and economics.

She started her career at the Coca-Cola Company where she worked as sensory specialist EMEA and in R&D focusing on adult sparkling drinks.

Since 2018 she has joined Rousselot as a Product and Business Development Manager to support the Rousselot business in North-West Europe. Since 2019, she is focusing on the business development of our Health & Nutrition segment in EMEA. In her role, she works together with existing and potential customer to find the perfect solution for new collagen based launches.